



Evaluation of Serum CXCL10 Level as a Prognostic Marker in Colorectal Cancer Patients: A Retrospective Cohort Study

Amir Hooshang Mohammadpoor¹, Kamran Ghaffarzadegan², Mehri Hasanpoor¹, Azra IZanloo², Soghra Mehri³, Mahdi Jannati¹ and Sepideh Elyasi^{1*}

¹Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

²Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran

³Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

*Corresponding author: Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Email: elyasis@mums.ac.ir

Received 2022 January 25; Accepted 2022 May 14.

Abstract

Background: One of the current challenges in cancer management is finding diagnostic and prognostic markers for various cancers. CXCL10 is a small protein that is defined as an 'inflammatory' chemokine and binds to CXCR3 to mediate immune responses through the activation and recruitment of leukocytes such as T cells, eosinophils, monocytes and natural killer cells. It facilitates the immune system antitumor activity, and causes tumor regression through induction of angiostasis and cellular apoptosis. Most previous studies have reported the anti-tumor activity of CXCR10, while studies on its role in colorectal cancer are limited.

Objectives: The present study aimed to evaluate the correlation of serum CXCL10 level with the prognosis of patients with colorectal cancer.

Methods: This retrospective cohort study was performed on 69 patients with a histopathological diagnosis of colorectal cancer in the oncology ward of Razavi Hospital, Mashhad, Iran, between July 2018 and September 2019. The relationship between the serum CXCL10 concentration and colorectal cancer prognosis was investigated.

Results: The results of Cox regression analysis indicated a significant relationship between the patients' mortality and metastasis rate and a high concentration of CXCL10 ($P = 0.018$ and $P = 0.045$, respectively); however, a high concentration of CXCL10 was not significantly correlated with the recurrence rate ($P = 0.81$) during the four-year follow-up.

Conclusions: The level of CXCL10 was significantly associated with incidence of mortality and metastasis in colorectal cancer patients during a four-year follow-up.

Keywords: Colorectal Cancer, CXCL10, CXCR3, Prognosis, Survival

1. Background

Colorectal cancer (CRC) is the third and fourth most common cancer in men and women worldwide, respectively. It is also the third most common cancer among women and the fifth most common cancer among men in Iran. Annually, more than 550,000 deaths in one million people are reported in patients with CRC (1). The prevalence and mortality rates of CRC are estimated to be high in developed countries and are also rapidly increasing in middle- and low-income populations (2). Globally, CRC accounts for 35% of all deaths due to cancer worldwide (3). According to the International Agency for Research on Cancer (IARC) report, the prevalence of CRC among men and women was 8.7 and 6.4 per 100,000 people in 2008, respectively (3).

The chemokine interferon- γ inducible protein 10 kDa

(CXCL10) is a member of the CXC chemokine family, which exerts its biological effects by binding to CXCR3 receptor. It contributes to leukocyte trafficking (chemotaxis), apoptosis, cell growth, and angiostatic effects (4). It is also involved in several human pathological conditions, including infections, chronic and prolonged inflammation, immune dysregulation and dysfunction, tumor growth and development, and metastasis (4). Under proinflammatory conditions, CXCL10 is secreted from various cells, including leukocytes (e.g., activated neutrophils, eosinophils (5, 6), monocytes, endothelial and epithelial cells, and fibroblasts). This vital regulator of interferon (IFN) response chemoattracts activated Th1 lymphocytes to the inflammation site, followed by Th1 immune responses (5, 7, 8). CXCL10 is also involved in chemotaxis of monocytes, T cells, and natural killer cells. Due to the prominent role of CXCL10 in the recruitment of leukocytes to the inflamma-

tion site, it may deteriorate inflammation and tissue damage (9).

More importantly, CXCL10 has been identified as a major biological marker of disease severity and may be used as a prognostic marker for various diseases, particularly cancers. The CXC family of chemokines is unique, as it can induce or inhibit angiogenesis, depending on the presence of glutamine-leucine-arginine (ELR) or ELR sequence in the molecular structure. CXCL10, which lacks the ELR sequence, inhibits angiogenesis and exerts antitumor effects (10-12). Nevertheless, high expression levels of CXCR3 and CXCL10 receptors have been reported in some advanced human cancers, such as malignant melanoma (13), ovarian carcinoma (14), multiple myeloma (15), B cell lymphoma, and basal cell carcinoma (16).

Generally, biomarkers play an important role in the diagnosis, prognosis, treatment, and monitoring of cancers. The use of serum tumor markers can be a simple and noninvasive method for cancer diagnosis and assessment of prognosis and patient survival (17). Studies in recent years have found promising molecular biomarkers to predict the prognosis of CRC patients, although none of these studies can be confirmed, and further research is essential. Besides, most previous studies have been performed on the carcinoembryonic antigen (CEA), which is known as a predictive marker of prognosis and relapse in patients. Among cytokines, CXCL10 is also known to play an important immunomodulatory role. It is also a chemotactic immune factor; therefore, it can be used as a prognostic factor in CRC patients (4).

2. Objectives

Based on the results of previous studies and the speculated relationship between the expression of the aforementioned biomarkers and the prognosis of CRC, the present study aimed to evaluate the level of CXCL10 as a serum biomarker in CRC patients to predict their prognosis and survival.

3. Methods

3.1. Study Population

This retrospective cohort study was performed on 70 patients with a histopathological diagnosis of CRC, presenting to the oncology ward of Razavi Hospital in Mashhad, Iran, between July 2018 and September 2019. The patients were followed-up for up to four years. At the onset of the study, the patients' demographic data, as well as information regarding the stage of cancer, chemotherapy regimen, and duration of therapy, was recorded. Besides, in-

formation on the patients' cancer status, including the primary tumor location, tumor size, histopathological type of tumor, degree of tumor differentiation, TNM stage, vascular and lymph node metastasis or invasion, and CEA level, was collected. On the other hand, patients with a metastatic disease at the time of diagnosis, a history of colorectal malignancy or surgery, inflammatory bowel disease, collagen vascular disease, and renal or hepatic failure were excluded from the study. Finally, the patient's cancer status was documented regarding survival, tumor metastasis, and recurrence over four years.

3.2. Serum CXCL10 Measurement

The patients' whole blood samples (10 mL) were collected from the brachial vein, transferred to the laboratory of Razavi Hospital, and centrifuged at 1000 rpm for 10 minutes. The plasma fraction was isolated and stored at -70°C until further analysis. The serum CXCL10 concentration was measured by a Boster Bio ELISA kit (USA) in September 2019.

3.3. Ethical Considerations

The present study was performed on pre-collected samples of patients, admitted to Razavi Hospital. Informed consent was obtained from the participants before the study. The patients' information was kept strictly confidential and was not disclosed to anyone by the researcher (ethics approval code: IR.MUMS.REC.1396.527).

3.4. Statistical Analysis

Statistical analysis was performed in SPSS version 19. Data are presented as mean \pm standard deviation (SD) and median (interquartile range) for continuous variables with normal and non-normal distributions, respectively, and as number (percentage) for nominal variables. Moreover, Kolmogorov-Smirnov test was used to assess the normal distribution of variables. Independent sample t-test and Mann-Whitney U tests were also used, respectively, to compare normally and non-normally distributed variables between the two groups. Besides, for comparison of more than two groups regarding normally and non-normally distributed variables, one-way ANOVA and Kruskal-Wallis tests were used, respectively. Besides, Pearson's correlation test (for data with a normal distribution) and Spearman's correlation test (for data with a non-normal distribution) were performed to examine the extent of correlation between two quantitative variables. All the tests were performed at a significance level of 0.05.

4. Results

A total of 69 patients were included in this study. The mean age of the patients was 65.12 ± 12.75 years, and 41% of the study population were female. Twelve patients expired in this study after diagnosis during the follow-up. Four patients (6%) experienced recurrence, and 11% (9) had metastatic manifestations. The demographic data of the patients are summarized in Table 1.

Table 1. Demographic Data of the Studied Patients^a

Variable	Value
Age (y)	65.4 \pm 12.75
Sex	
Male	40 (57.97)
Female	59 (42.03)
Survival rate	57 (82.61)
Metastasis	8 (11.59)
Recurrence rate	4 (5.8)

^a Values are expressed as mean \pm SD or No. (%).

According to the data presented in Table 2, the mean age of the patients was 65 ± 13.47 years in males and 11.88 ± 65 years in females ($P = 0.85$). The CEA and serum CXCL10 levels were not significantly different between males and females. However, the concentration of CXCL10 was lower in women than in men ($P = 0.081$). The results of this study showed that two female patients and 10 male patients expired during the study. Although there was no significant difference in terms of survival between men and women ($P = 0.054$), the incidence of mortality was higher in men than in women. The results revealed that six female patients and two male patients developed metastasis during the study. The results of statistical analysis also showed a significant difference between males and females regarding metastasis occurrence ($P = 0.047$).

The relative risk of mortality, metastasis, and recurrence in association with the serum concentration of CXCL10 is shown in Table 3. According to the Wald test, the serum CXCL10 level had a significant correlation with mortality and metastasis, but not with the recurrence rate. Similar results were obtained according to the Cox regression analysis. The normal range of CXCL10 in healthy individuals is between 24 pg/mL and 933 pg/mL. Accordingly, the CXCL10 concentrations were classified into two groups: A CXCL10 concentration > 933 pg/mL and a CXCL10 concentration < 933 pg/mL. The results of Cox regression analysis showed a significant relationship between the incidence of mortality and a high concentration of CXCL10 ($P = 0.018$). The results of Cox regression analysis also showed a sig-

Table 2. Comparison of the Patients' Characteristics Between Males and Females^a

	Male	Female	P-Value
Age (y) ^b	65.63 \pm 13.47	65.07 \pm 11.88	0.85
CEA (ng/mL) ^b	4.28 \pm 5.38	3.67 \pm 0.99	0.67
CXCL10 (pg/mL) ^b	366.59 \pm 458.06	232.94 \pm 105.46	0.081
Survival^c			0.054
Alive	30 (75.0)	27 (93.1)	
Deceased	10 (25.0)	2 (6.9)	
Metastasis^c			0.047
None	38 (95)	23 (79.31)	
Metastatic	2 (5)	6 (21.4)	

^a The results are reported as mean \pm SD or No. (%).

^b Student *t*-test was used for data analysis.

^c Chi-square test was used for data analysis.

nificant relationship between metastasis and a high concentration of CXCL10 ($P = 0.045$). In other words, patients with a CXCL10 concentration above 933 pg/mL were more likely to develop metastasis. However, no significant relationship was found between the relative risk of recurrence and CXCL10 concentration in CRC patients during the four-year follow-up ($P = 0.81$) (Table 4).

Table 3. Relative Risk of Mortality, Metastasis, and Recurrence in Association with the Serum CXCL10 Concentration in Patients with Colorectal Cancer During a Four-Year Follow-Up

	OR (95% CI)	Wald Test	P-Value ^a
Mortality	1.002 (1.0 - 1.003)	5.119	0.024
Metastasis	1.002 (1.00 - 1.004)	4.454	0.035
Recurrence	1.00 (0.997 - 1.004)	0.05	0.82

^a Statistical analysis was performed using Cox regression analysis.

Table 4. Relative Risk of Mortality, Metastasis, and Recurrence in Patients with Colorectal Cancer During a Four-Year Follow-Up

	In a Normal Range (24 - 933)	Wald Test	P-Value ^a
CXCL10	Reference (< 933)		
RR of mortality	7.83 (1.412 - 43.127)	5.548	0.018**
RR of metastasis	17.12 (1.062 - 276.11)	4.01	0.045**
RR of recurrence	17.12 (1.062 - 276.11)	0.056	0.81

Abbreviation: RR, relative risk

^a Statistical analysis was performed using Cox regression analysis.

5. Discussion

The results of the present study showed that the serum concentration of CXCL10 was significantly associated with

the incidence of mortality and metastasis in CRC patients. Patients with a serum CXCL10 concentration above 933 pg/mL were more exposed to cancer-related mortality and metastasis. The results of Cox regression analysis showed no significant relationship between the relative risk of recurrence and CXCL10 concentration in CRC patients during the four-year follow-up.

Several studies have investigated the role of CXCL10 as a prognostic factor in CRC. In this regard, a study by Dimberg et al. in 2014 found that CXCL10 levels were significantly higher in CRC-affected tissues compared to the healthy tissues of CRC patients. Besides, the plasma level of CXCL10 was significantly higher in patients with CRC compared to the control group (18). It was concluded that assessment of changes in the plasma and tissue concentrations of CXCL10 in CRC patients may be useful in predicting clinical findings, such as recurrence, metastasis, lymph node involvement, and further pathological stages (18).

In a study by Jiang et al. in 2010, examining 64 stage II and III CRC patients, no significant correlation was found between the level of CXCL10 according to immunostaining and the tumor location, tumor size, histological type, lymphovascular invasion, perineural invasion, or TNM stage (19). However, patients with lower levels of CXCL10 expression showed a poorer prognosis (19). In another study by Zipin-Roitman et al. on CRC cell lines, the expression of CXCL10 and CXCR3 was induced by IFN-gamma in these cells. However, this chemokine did not affect tumor growth characteristics or angiogenesis-related functions. CXCL10 also significantly increased the invasion-related properties of these cells (20).

Additionally, a study by Toiyama et al. in 2012 on 218 CRC patients and 17 healthy individuals showed that the serum CXCL10 levels increased as the disease progressed in CRC patients (21). The serum CXCL10 level was also significantly associated with the pathological stage of tumor, vascular invasion, and distant metastasis. Also, high levels of CXCL10 had a significant association with low survival in all stages of CRC, which is consistent with the findings of the present study (21). A study by Bai et al. in 2016 on 143 patients with stage II CRC found that the overexpression of CXCL10 and CXCR3 could be prognostic factors in patients and might be associated with clinical outcomes, such as recurrence and lymph node involvement (22).

Moreover, a study in 2012 by Wu et al. on patients with CRC found that CXCR3 mRNA expression was significantly higher in the primary colorectal tumor tissue compared to non-cancerous colon tissue (23). The expression of CXCR3 was detected in 98 out of 112 patients. Therefore, CXCR3 may play a key role in the development of CRC. By analyzing the correlation between the clinicopathological factors and the expression of CXCR3, it was concluded that

a high level of CXCR3 expression was significantly correlated with tumor differentiation, tumor size, lymph node involvement, and distant metastasis. Also, patients with high levels of CXCR3 expression had lower survival rates than patients with lower CXCR3 expression levels. The results of this study are in line with the findings of a recent study, which showed a significant relationship between the serum CXCL10 level and mortality and metastasis (23). Another study in 2014 by Comstock et al. on 126 asymptomatic men revealed that high levels of CXCL10 significantly induced tubular adenomas in patients (24). It was also found that in patients with more than three colorectal polyps, CXCL10 showed an increasing pattern (24).

As mentioned earlier, available studies on the serum level of CXCL10, as a prognostic factor in CRC patients, have reported some controversial findings, and further detailed research is essential. One reason for the contradictory results of these studies is the presence of some important confounding factors, such as metastatic disease at the time of diagnosis, history of colorectal malignancy or surgery, inflammatory bowel disease, collagen vascular disease, and renal or hepatic failure. However, in the current study, these cases were considered as the exclusion criteria. Unlike other studies, we attempted to exclude all important confounding factors influencing the serum concentration of CXCL10. Therefore, the main difference between the present study and previous research is the higher accuracy of this study in the evaluation of CXCL10 as a prognostic factor by removing the confounding factors.

Another possible mechanism to explain the difference between the results of these studies is the dual role of CXCL10 in cell growth. The proliferative and anti-proliferative effects of CXCL10 are cell-specific and related to the receptor subtype expressed at the cell surface. There are three variants of CXCR3, including CXCR3-A, CXCR3-B, and CXCR3-alt. Different cells express different patterns of these three receptor isoforms. Besides, different CXCR3 isoforms mediate the opposing effects of CXCL10 on proliferation. The anti-proliferative effects of CXCL10 are mediated by the CXCR3-B isoform. This receptor couples with G α s, activates adenylate cyclase, and inhibits endothelial cell proliferation and migration (25); this seems to be the key mechanism in the anti-proliferative effects of CXCL10. Moreover, this receptor subtype does not result in chemotaxis (25). Cells that contain this receptor include endometrial malignancies, glioblastoma, and colorectal malignancies. The migration of CXCR3-positive T cells to inflammatory or neoplastic regions is mediated by CXCL10 and is also associated with the inhibitory effects of tumor progression and anti-metastasis effects (26).

The CXCR3-B isoform, as a common receptor for all four types of angiostatic chemokines (CXCL4, CXCL9, CXCL10,

and CXCL11), provides a better understanding of the role of CXC chemokines in inflammatory cells. It is known to regulate inflammatory responses, leading to angiostasis and inhibition of endothelial cell proliferation (27). Besides, CXCL10 lacks the ELR sequence, inhibits angiogenesis, and exerts antitumor effects (4). However, the high expression of CXCR3 and CXCL10 receptors has been observed in some advanced human cancers, such as malignant melanoma (13), ovarian carcinoma (14), multiple myeloma (15), B-cell lymphoma, and basal cell carcinoma (16). In the CNS microglia, astrocytes and even neurons express and secrete CXCL10. CXCL10 results in the chemotaxis of microglial cells into the CNS circulation. The CXCL10/CXCR3 signaling also increases in some CNS-related pathological conditions (28). Generally, studies on a larger sample size of patients, considering all characteristics of patients that may be involved in the prognosis of cancer, are recommended for reaching a more definitive conclusion.

5.1. Conclusions

The results of this study showed that the serum concentration of CXCL10 was significantly associated with the mortality and metastasis of CRC patients.

Footnotes

Authors' Contribution: Study concept and design: A. M. and S. E.; acquisition of data: M. H., K. G., and S. M.; analysis and interpretation of data: A. I. and S. E.; drafting of the manuscript: M. J.; critical revision of the manuscript for important intellectual content: S. E. and A. M.; statistical analysis: S. E. and A. M.; administrative, technical, and material support: A. M. and K. G.; study supervision: A. M.

Conflict of Interests: There was no conflict of interest in this study.

Data Reproducibility: It was not declared by the authors.

Ethical Approval: This research was reviewed and approved by local Ethics Committee of Mashhad University of Medical Sciences (code: IR.MUMS.REC.1396.527).

Funding/Support: Razavi Hospital of Mashhad (Mashhad, Iran) funded this study.

Informed Consent: The present study was performed on pre-collected samples of patients admitted to Razavi Hospital, and informed consent was obtained from the participants before the study.

References

- Hagggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clin Colon Rectal Surg.* 2009;22(4):191-7. doi: 10.1055/s-0029-1242458. [PubMed: 21037809]. [PubMed Central: PMC2796096].
- Boyle P, Langman JS. ABC of colorectal cancer: Epidemiology. *BMJ.* 2000;321(7264):805-8. doi: 10.1136/bmj.321.7264.805. [PubMed: 11009523]. [PubMed Central: PMC118620].
- Pahlavan PS, Jensen K. A short impact of epidemiological features of colorectal cancer in Iran. *Tumori.* 2005;91(4):291-4. [PubMed: 16277091].
- Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (Review). *Oncol Lett.* 2011;2(4):583-9. doi: 10.3892/ol.2011.300. [PubMed: 22848232]. [PubMed Central: PMC3406435].
- Dyer KD, Percopo CM, Fischer ER, Gabryszewski SJ, Rosenberg HF. Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. *Blood.* 2009;114(13):2649-56. doi: 10.1182/blood-2009-01-199497. [PubMed: 19652202]. [PubMed Central: PMC2756124].
- Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1) and Th2s. *J Exp Med.* 1998;187(1):129-34. doi: 10.1084/jem.187.1.129. [PubMed: 9419219]. [PubMed Central: PMC2199181].
- Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. *J Exp Med.* 2001;193(8):975-80. doi: 10.1084/jem.193.8.975. [PubMed: 11304558]. [PubMed Central: PMC2193411].
- Khan IA, MacLean JA, Lee FS, Casciotti L, DeHaan E, Schwartzman JD, et al. IP-10 is critical for effector T cell trafficking and host survival in *Toxoplasma gondii* infection. *Immunity.* 2000;12(5):483-94. doi: 10.1016/S1074-7613(00)80200-9. [PubMed: 10843381].
- Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. *Autoimmun Rev.* 2009;8(5):379-83. doi: 10.1016/j.autrev.2008.12.002. [PubMed: 19105984].
- Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. *J Exp Med.* 1995;182(1):155-62. doi: 10.1084/jem.182.1.155. [PubMed: 7540647]. [PubMed Central: PMC2192108].
- Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene therapy of cancer: current status and future prospects. *Mol Aspects Med.* 2007;28(1):87-114. doi: 10.1016/j.mam.2006.12.005. [PubMed: 17306361].
- Belperio JA, Keane MP, Arenberg DA, Addison C, Ehlerl JE, Burdick MD, et al. CXC chemokines in angiogenesis. *J Leukocyte Biol.* 2000;68(1):1-8.
- Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. *J Clin Pathol.* 2007;60(6):596-9. doi: 10.1136/jcp.2005.032144. [PubMed: 16522748]. [PubMed Central: PMC1955073].
- Furuya M, Suyama T, Usui H, Kasuya Y, Nishiyama M, Tanaka N, et al. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. *Hum Pathol.* 2007;38(11):1676-87. doi: 10.1016/j.humpath.2007.03.023. [PubMed: 17707463].
- Pellegrino A, Antonaci F, Russo F, Merchionne F, Ribatti D, Vacca A, et al. CXCR3-binding chemokines in multiple myeloma. *Cancer Lett.* 2004;207(2):221-7. doi: 10.1016/j.canlet.2003.10.036. [PubMed: 15072832].
- Lo BK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. *Am J Pathol.* 2010;176(5):2435-46. doi: 10.2353/ajpath.2010.081059. [PubMed: 20228225]. [PubMed Central: PMC2861108].
- Compton CC, Tanabe KK, Savarese D. *Pathology and prognostic determinants of colorectal cancer.* Wellesley, Massachusetts, USA: UpToDate; 2016. Available from: <https://www.medilib.ir/upupdate/show/2484>.
- Dimberg J, Skarstedt M, Lofgren S, Zar N, Matussek A. Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer. *Biomed Rep.* 2014;2(3):340-3. doi: 10.3892/br.2014.255. [PubMed: 24748971]. [PubMed Central: PMC3990219].

19. Jiang Z, Xu Y, Cai S. CXCL10 expression and prognostic significance in stage II and III colorectal cancer. *Mol Biol Rep*. 2010;**37**(6):3029–36. doi: [10.1007/s11033-009-9873-z](https://doi.org/10.1007/s11033-009-9873-z). [PubMed: [19821051](https://pubmed.ncbi.nlm.nih.gov/19821051/)].
20. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. *Cancer Res*. 2007;**67**(7):3396–405. doi: [10.1158/0008-5472.CAN-06-3087](https://doi.org/10.1158/0008-5472.CAN-06-3087). [PubMed: [17409450](https://pubmed.ncbi.nlm.nih.gov/17409450/)].
21. Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, et al. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. *Int J Oncol*. 2012;**40**(2):560–6. doi: [10.3892/ijco.2011.1247](https://doi.org/10.3892/ijco.2011.1247). [PubMed: [22038159](https://pubmed.ncbi.nlm.nih.gov/22038159/)].
22. Bai M, Chen X, Ba YI. CXCL10/CXCR3 overexpression as a biomarker of poor prognosis in patients with stage II colorectal cancer. *Mol Clin Oncol*. 2016;**4**(1):23–30. doi: [10.3892/mco.2015.665](https://doi.org/10.3892/mco.2015.665). [PubMed: [26870351](https://pubmed.ncbi.nlm.nih.gov/26870351/)]. [PubMed Central: [PMC4726926](https://pubmed.ncbi.nlm.nih.gov/PMC4726926/)].
23. Wu Q, Dhir R, Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. *Mol Cancer*. 2012;**11**:3. doi: [10.1186/1476-4598-11-3](https://doi.org/10.1186/1476-4598-11-3). [PubMed: [22236567](https://pubmed.ncbi.nlm.nih.gov/22236567/)]. [PubMed Central: [PMC3320557](https://pubmed.ncbi.nlm.nih.gov/PMC3320557/)].
24. Comstock SS, Hortos K, Kovan B, McCaskey S, Pathak DR, Fenton JI. Adipokines and obesity are associated with colorectal polyps in adult males: a cross-sectional study. *PLoS One*. 2014;**9**(1). e85939. doi: [10.1371/journal.pone.0085939](https://doi.org/10.1371/journal.pone.0085939). [PubMed: [24465801](https://pubmed.ncbi.nlm.nih.gov/24465801/)]. [PubMed Central: [PMC3895019](https://pubmed.ncbi.nlm.nih.gov/PMC3895019/)].
25. Ji R, Lee CM, Gonzales LW, Yang Y, Aksoy MO, Wang P, et al. Human type II pneumocyte chemotactic responses to CXCR3 activation are mediated by splice variant A. *Am J Physiol Lung Cell Mol Physiol*. 2008;**294**(6):L1187–96. doi: [10.1152/ajplung.00388.2007](https://doi.org/10.1152/ajplung.00388.2007). [PubMed: [18375741](https://pubmed.ncbi.nlm.nih.gov/18375741/)].
26. Enderlin M, Kleinmann EV, Struyf S, Buracchi C, Vecchi A, Kinscherf R, et al. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. *Cancer Gene Ther*. 2009;**16**(2):149–60. doi: [10.1038/cgt.2008.62](https://doi.org/10.1038/cgt.2008.62). [PubMed: [18670452](https://pubmed.ncbi.nlm.nih.gov/18670452/)].
27. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. *Trends Immunol*. 2004;**25**(4):201–9. doi: [10.1016/j.it.2004.02.006](https://doi.org/10.1016/j.it.2004.02.006). [PubMed: [15039047](https://pubmed.ncbi.nlm.nih.gov/15039047/)].
28. Vinet J, de Jong EK, Boddeke HW, Stanulovic V, Brouwer N, Granic I, et al. Expression of CXCL10 in cultured cortical neurons. *J Neurochem*. 2010;**112**(3):703–14. doi: [10.1111/j.1471-4159.2009.06495.x](https://doi.org/10.1111/j.1471-4159.2009.06495.x). [PubMed: [19919575](https://pubmed.ncbi.nlm.nih.gov/19919575/)].